US Stock Insider Trading | Veracyte disclosed 7 insider transactions on March 6

On March 6, 2026, Veracyte (VCYT) disclosed seven insider trading transactions by company insiders. Director Stapley Marc sold 26.3k shares on March 4, 2026.

【Recent Insider Transactions】

【Company Information】

Veracyte, Inc. was incorporated as Calderome Holdings on August 15, 2006, in Delaware.

Until early 2008, Calderome operated as a startup incubator. On March 4, 2008, the company was renamed Veracyte Ltd. Veracyte is a pioneering diagnostics company in the field of molecular cytology, aiming to improve patient outcomes and reduce healthcare costs. The company specializes in achieving accurate diagnoses for diseases that often require invasive procedures—many healthy patients undergo costly interventions that are ultimately proven to be unnecessary. The company derives clinically actionable genomic information from collecting outpatient cytology specimens, improving the diagnostic accuracy of patient care at an earlier stage. The company’s first commercial solution—Afirma Thyroid FNA Analysis—includes its core gene expression classifier (GEC). GEC helps physicians reduce the number of unnecessary surgeries by using proprietary 142-gene markers to preoperatively determine whether thyroid nodules, previously classified as indeterminate by cytopathology, can be reclassified as benign. The company’s business headquarters is located in South San Francisco, California, and Austin, Texas, and it operates within a department.